Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers, develops, and provides small molecule drugs targeting signaling pathways critical to disease mechanisms. The company's primary focus is on hematologic disorders, cancer, and rare immune diseases. Rigel's commercial portfolio consists of three FDA-approved products: TAVALISSE (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP); REZLIDHIA (olutasidenib), a targeted therapy for relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation; and GAVRETO (pralsetinib), a kinase inhibitor for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancer. In 2024, Rigel generated $179.3 million in total revenue, which included $104.8 million from TAVALISSE, $23.0 million from REZLIDHIA, $17.1 million from GAVRETO, and $34.4 million in contract revenue from collaborations. The company also maintains a clinical development pipeline, including R289, an oral IRAK1/4 inhibitor being evaluated for lower-risk myelodysplastic syndrome. Rigel leverages strategic partnerships and licensing agreements to expand the reach of its therapies, collaborating with institutions like The University of Texas MD Anderson Cancer Center and various pharmaceutical partners.
